Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Language
Publication year range
1.
Eur J Clin Pharmacol ; 79(11): 1425-1442, 2023 Nov.
Article in English | MEDLINE | ID: mdl-37650923

ABSTRACT

PURPOSE: Investigate inhaled nitric oxide's influence on mortality rates, mechanical ventilation and cardiopulmonary bypass duration, and length of stay in the intensive care unit and hospital when administered during cardiopulmonary bypass. METHODS: Following the PRISMA guidelines, we searched four electronic databases (PubMed, EMBASE, Cochrane Library, and Web of Science) up to 4th March 2023. The protocol was registered in the PROSPERO database with ID: CRD42023423007. Using Review Manager software, we reported outcomes as risk ratios (RRs) or mean difference (MD) and confidence intervals (CIs). RESULTS: The meta-analysis included a total of 17 studies with 2897 patients. Overall, there were no significant differences in using nitric oxide over control concerning mortality (RR = 1.03, 95% CI 0.73 to 1.45; P = 0.88) or cardiopulmonary bypass duration (MD = -0.14, 95% CI - 0.96 to 0.69; P = 0.74). The intensive care unit days were significantly lower in the nitric oxide group than control (MD = -0.80, 95% CI - 1.31 to -0.29; P = 0.002). Difference results were obtained in terms of the length of stay in the hospital according to sensitivity analysis (without sensitivity [MD = -0.41, 95% CI - 0.79 to -0.02; P = 0.04] vs. with sensitivity [MD = -0.31, 95% CI - 0.69 to 0.07; P = 0.11]. Subgroup analysis shows that, in children, nitric oxide was favored over control in significantly reducing the duration of mechanical ventilation (MD = -4.58, 95% CI - 5.63 to -3.53; P < 0.001). CONCLUSION: Using inhaled nitric oxide during cardiopulmonary bypass reduces the length of stay in the intensive care unit, and for children, it reduces the duration of mechanical ventilation.


Subject(s)
Cardiopulmonary Bypass , Nitric Oxide , Humans , Child , Adult , Intensive Care Units , Respiration, Artificial
2.
Korean J Parasitol ; 51(1): 93-8, 2013 Feb.
Article in English | MEDLINE | ID: mdl-23467705

ABSTRACT

A field applicable diagnostic technique, the dipstick assay, was evaluated for its sensitivity and specificity in diagnosing human Schistosoma mansoni infection. A monoclonal antibody (mAb) against S. mansoni adult worm tegumental antigen (AWTA) was employed in dipstick and sandwich ELISA for detection of circulating schistosome antigen (CSA) in both serum and urine samples. Based on clinical and parasitological examinations, 60 S. mansoni-infected patients, 30 patients infected with parasites other than schistosomiasis, and 30 uninfected healthy individuals were selected. The sensitivity and specificity of dipstick assay in urine samples were 86.7% and 90.0%, respectively, compared to 90.0% sensitivity and 91.7% specificity of sandwich ELISA. In serum samples, the sensitivity and specificity were 88.3% and 91.7% for dipstick assay vs. 91.7% and 95.0% for sandwich ELISA, respectively. The diagnostic efficacy of dipstick assay in urine and serum samples was 88.3% and 90.0%, while it was 90.8% and 93.3% for sandwich ELISA, respectively. The diagnostic indices of dipstick assay and ELISA either in serum or in urine were statistically comparable (P>0.05). In conclusion, the dipstick assay offers an alternative simple, rapid, non-invasive technique in detecting CSA or complement to stool examinations especially in field studies.


Subject(s)
Antigens, Helminth/blood , Antigens, Helminth/urine , Diagnostic Tests, Routine/methods , Parasitology/methods , Point-of-Care Systems , Schistosoma mansoni/isolation & purification , Schistosomiasis mansoni/diagnosis , Animals , Antibodies, Helminth/isolation & purification , Antibodies, Monoclonal/isolation & purification , Humans , Immunoassay/methods , Schistosoma mansoni/immunology , Sensitivity and Specificity
3.
Mem Inst Oswaldo Cruz ; 105(6): 729-35, 2010 Sep.
Article in English | MEDLINE | ID: mdl-20944985

ABSTRACT

This work aimed to evaluate the effect of diphenyl dimethyl bicarboxylate (DDB) and dexamethasone alone and in combination with praziquantel on various parasitological, immunological and pathological parameters reflecting disease severity and morbidity in murine schistosomiasis. DDB and dexamethasone had no effect on worm burden but altered tissue egg distribution. This indicates that, under the schedule used, neither drug interfered with the development of adult worms or oviposition, but both can modulate liver pathology. Dexamethasone resulted in a greater reduction in granuloma size than did DDB. Dexamethasone-treated mice also showed lower levels of serum gamma interferon (IFN-γ), interleukin-12 (IL-12) and IL-4, together with higher IL-10 levels, than infected untreated control animals. These data suggest that dexamethasone is a convenient and promising coadjuvant agent that results in decreased morbidity in murine schistosomiasis.


Subject(s)
Adjuvants, Immunologic/therapeutic use , Anthelmintics/therapeutic use , Dexamethasone/therapeutic use , Dioxoles/therapeutic use , Glucocorticoids/therapeutic use , Praziquantel/therapeutic use , Schistosomiasis mansoni/drug therapy , Adjuvants, Immunologic/administration & dosage , Animals , Anthelmintics/administration & dosage , Cytokines/blood , Cytokines/immunology , Dexamethasone/administration & dosage , Dioxoles/administration & dosage , Drug Therapy, Combination/methods , Glucocorticoids/administration & dosage , Granuloma/parasitology , Granuloma/pathology , Liver/parasitology , Liver/pathology , Male , Mice , Praziquantel/administration & dosage , Schistosomiasis mansoni/immunology , Schistosomiasis mansoni/parasitology , Schistosomiasis mansoni/pathology , Severity of Illness Index
4.
Mem. Inst. Oswaldo Cruz ; 105(6): 729-735, Sept. 2010. tab
Article in English | LILACS | ID: lil-560655

ABSTRACT

This work aimed to evaluate the effect of diphenyl dimethyl bicarboxylate (DDB) and dexamethasone alone and in combination with praziquantel on various parasitological, immunological and pathological parameters reflecting disease severity and morbidity in murine schistosomiasis. DDB and dexamethasone had no effect on worm burden but altered tissue egg distribution. This indicates that, under the schedule used, neither drug interfered with the development of adult worms or oviposition, but both can modulate liver pathology. Dexamethasone resulted in a greater reduction in granuloma size than did DDB. Dexamethasone-treated mice also showed lower levels of serum gamma interferon (IFN-γ), interleukin-12 (IL-12) and IL-4, together with higher IL-10 levels, than infected untreated control animals. These data suggest that dexamethasone is a convenient and promising coadjuvant agent that results in decreased morbidity in murine schistosomiasis.


Subject(s)
Animals , Male , Mice , Adjuvants, Immunologic , Anthelmintics , Dexamethasone , Dioxoles , Glucocorticoids , Praziquantel , Schistosomiasis mansoni , Adjuvants, Immunologic , Anthelmintics , Cytokines/blood , Cytokines/immunology , Dexamethasone , Dioxoles , Drug Therapy, Combination/methods , Glucocorticoids , Granuloma , Granuloma/pathology , Liver , Liver/pathology , Praziquantel , Severity of Illness Index , Schistosomiasis mansoni/immunology , Schistosomiasis mansoni , Schistosomiasis mansoni/pathology
SELECTION OF CITATIONS
SEARCH DETAIL
...